Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for Acute Exacerbations Requiring Hospitalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test)~* Smoking history of at least 10 pack-years (10 pack-years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years, etc.)~* Current hospitalization for potential infectious AECOPD treated with standard therapy~* History of at least one exacerbation during the last year (prior to the current hospital admission) for which systemic steroids and/or antibiotics were taken~* ECG at admission~Exclusion Criteria:~* Mechanical or non-invasive ventilation at moment of randomization (D1)~* Long QT interval on ECG (QTc \> 450msec for males or \> 470msec for females)~* History of life-threatening arrhythmias~* Myocardial infarction (NSTEMI or STEMI) less than 6 weeks before start of study drug~* Unstable angina pectoris or acute myocardial infarction (NSTEMI or STEMI) at admission~* Drugs with high risk for long QT interval and torsade de pointes (amiodarone, flecainide, procainamide, sotalol, droperidol, haldol, citalopram, other macrolides)~* Documented uncorrected severe hypokalemia (K+ \< 3.0 mmol/L) or hypomagnesemia (Mg2+ \< 0.5 mmol/L)~* Chronic systemic steroids (\> 4 mg methylprednisolone /day for ≥ 2 months)~* Actual use of macrolides for at least 2 weeks~* Allergy to macrolides~* Active cancer treatment~* Life expectancy \< 3 months~* Pregnant or breast-feeding subjects. Woman of childbearing potential must have a pregnancy test performed and a negative result must be documented before start of treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): N = 250~* From day 1 up to and including day 3: 500 mg azithromycin PO once a day~* From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
- Placebo (Type: PLACEBO_COMPARATOR): N = 250~* From day 1 up to and including day 3: 500 mg placebo PO once a day~* From day 4 up to and including day 90: 250 mg placebo PO once every 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).